A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
Public ClinicalTrials.gov record NCT04092270. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or low grade ovarian cancer that has come back after a period of improvement (recurrent). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving peposertib and pegylated liposomal doxorubicin hydrochloride may work better in treating patients with ovarian cancer compared to pegylated liposomal doxorubicin hydrochloride alone.
Study identification
- NCT ID
- NCT04092270
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 55 participants
Conditions and interventions
Conditions
- Endometrial High Grade Endometrioid Adenocarcinoma
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube High Grade Serous Adenocarcinoma
- Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Fallopian Tube Undifferentiated Carcinoma
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
- FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
- Ovarian High Grade Serous Adenocarcinoma
- Ovarian Seromucinous Carcinoma
- Ovarian Undifferentiated Carcinoma
- Platinum-Sensitive Ovarian Carcinoma
- Primary Peritoneal Carcinosarcoma
- Primary Peritoneal High Grade Serous Adenocarcinoma
- Primary Peritoneal Transitional Cell Carcinoma
- Primary Peritoneal Undifferentiated Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Ovarian Clear Cell Adenocarcinoma
- Recurrent Ovarian Endometrioid Adenocarcinoma
- Recurrent Ovarian Low Grade Serous Adenocarcinoma
- Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor
- Recurrent Ovarian Mucinous Adenocarcinoma
- Recurrent Ovarian Transitional Cell Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
Interventions
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Echocardiography Test Procedure
- Magnetic Resonance Imaging Procedure
- Multigated Acquisition Scan Procedure
- Pegylated Liposomal Doxorubicin Hydrochloride Drug
- Peposertib Drug
Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 7, 2020 (Actual)
- Primary completion
- Feb 12, 2026 (Actual)
- Completion
- Jun 8, 2027 (Estimated)
- Last update posted
- Jul 20, 2026
2020 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCHealth University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Memorial Sloan Kettering Monmouth | Middletown | New Jersey | 07748 | — |
| Memorial Sloan Kettering Westchester | Harrison | New York | 10604 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania | 15232 | — |
| University of Virginia Cancer Center | Charlottesville | Virginia | 22908 | — |
| University of Wisconsin Carbone Cancer Center - University Hospital | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04092270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04092270 live on ClinicalTrials.gov.